quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:26·22d
SECFiling
Sutro Biopharma Inc. logo

SEC Form EFFECT filed by Sutro Biopharma Inc.

STRO· Sutro Biopharma Inc.
Health Care
Original source

Companies

  • STRO
    Sutro Biopharma Inc.
    Health Care

Recent analyst ratings

  • Apr 7UpdateLeerink Partners$38.00
  • Mar 24UpdateWells Fargo$27.00
  • Mar 24UpdateH.C. Wainwright$28.00
  • Jan 20UpdateCitizens JMP$23.00
  • Jun 16UpdatePiper Sandler$2.00
  • Mar 17UpdateH.C. Wainwright-

Related

  • SEC1d
    SEC Form DEFA14A filed by Sutro Biopharma Inc.
  • SEC1d
    SEC Form DEF 14A filed by Sutro Biopharma Inc.
  • SEC2d
    Amendment: SEC Form SCHEDULE 13G/A filed by Sutro Biopharma Inc.
  • SEC2d
    SEC Form SCHEDULE 13G filed by Sutro Biopharma Inc.
  • PR4d
    Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
  • ANALYST16d
    Leerink Partners initiated coverage on Sutro Biopharma with a new price target
  • SEC22d
    SEC Form 424B3 filed by Sutro Biopharma Inc.
  • ANALYST30d
    Sutro Biopharma upgraded by Wells Fargo with a new price target
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022